Roswell Park Comprehensive Cancer Center: Sequencing Study From Roswell Park Highlights Previously Unknown Myeloma Resistance Mechanisms
December 08, 2020
December 08, 2020
BUFFALO, New York, Dec. 8 (TNSRes) -- The Roswell Park Comprehensive Cancer Center issued the following news release:
A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma. Findings from the study will be presented today at the . . .
A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma. Findings from the study will be presented today at the . . .